EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008

Size: px

Start display at page:

Download "EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008"

Angelica Fowler
6 years ago
Views:

1 Work plan for

2 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2

3 The ETP is operated Mission To propose and to facilitate the priorities of Europe s NanoMedicine translational research program moving concepts from the laboratory to in vivo validation To guide the development of the social, regulatory and reimbursement environment To facilitate communication between key stakeholders on the progress made To use Healthcare leadership to drive and encourage new product concepts from academia To improve healthcare provision for patients and to improve the competitiveness of companies within Europe 3

ETP members Focus on companies Who are committed to achieve a leadership in nanomedicine Who are willing to bring nanotechnology to patients and market Academia and healthcare providers are essential

4 ETP members Focus on companies Who are committed to achieve a leadership in nanomedicine Who are willing to bring nanotechnology to patients and market Academia and healthcare providers are essential partners for developing nanomedicine Projects focused on translational research Focusing on diseases with significant economic impact the ETP is not another trade association, but an organisation that highlights issues for existing organisations 4

5 Current industrial membership Large scale Philips Medical Systems Siemens Medical Solutions STMicro Roche Diagnostics SMEs Nanobiotix Vermon Tigenix Cellmatrix To be completed with Marton 5

6 Outline of the work plan 2008 Research implementation Education & training Shaping the business, social, regulatory and reimbursement environment Communication & dissemination Outreach 6

7 Research implementation Influencing the definition of the FP7 work programmes / call topics Needs, concerns and gaps expressed by industry Complementary inputs from academia Final prioritisation of topics by Working Groups Action on relevant European programme committees Action at high level on relevant European Commission services Update of the research priorities listed in the SRA, by WGs Monitoring state of the art developments Monitoring of topics and projects supported by previous EU and national calls Technology exchange platforms organised at general assemblies Actions by Working Groups to explore new horizons/r&d A work plan with deliverables will be provided annually by each WG Workshops, Brainstorming groups Partnering and call aligned events at general assemblies for facilitating better projects and consortia 7

8 Research priorities for

9 Proposed research priorities Inspired by the Strategic Research Agenda Discussed by the working group on Nanotech based diagnostics and imaging 9

Nanodiagnostics #1 Nanotech based diagnostics for in vivo and/or in vitro early detection and/or therapy monitoring in the cardiovascular diseases, neurodegenerative diseases and cancer Technical

10 Nanodiagnostics #1 Nanotech based diagnostics for in vivo and/or in vitro early detection and/or therapy monitoring in the cardiovascular diseases, neurodegenerative diseases and cancer Technical content / scope Micro- and nanotechnology based solutions for early detection and/or therapy monitoring or cardiovascular conditions, neurodegenerative diseases and cancer. Funding scheme Large-scale integrating collaborative projects Specific features Active participation of industrial partners Active participation of clinical partners In the case of in vitro solutions, clinical tests should be demonstrated Preclinical tests are required for the in vivo applications, 10

11 Nanodiagnostics #2 Integrated diagnostic test (incl. sample preparation) for rapid and early diagnosis of viral and bacterial infection. Technical content / scope Micro- and nanotechnology based solutions for early and high sensitivity detection and/or monitoring of infectious diseases. Funding scheme Large scale integrating collaborative projects Specific features Active participation of industrial partners Active participation of medical partners Fully integrated solutions combining hardware and associated software 11

Project proposal guidance To ensure that research proposals lead to products within a decade, project proposals will need to plan for pre-clinical validation

12 Project proposal guidance To ensure that research proposals lead to products within a decade, project proposals will need to plan for pre-clinical validation within 5 years Guidelines will be issued to advise on the key technology and disease areas where the likelihood of achieving profitable success is greatest 12

Education & training Identify educational gaps to respond to the needs of industry, healthcare providers and academia in nanomedicine Stimulate

13 Education & training Identify educational gaps to respond to the needs of industry, healthcare providers and academia in nanomedicine Stimulate universities and training organisations in implementing courses and training for scientists, engineers, technicians and clinicians in nanomedicine related topics 13

14 Shaping the business, social, regulatory and reimbursement environment Influencing the regulatory bodies dealing with nanomedicine Identify issues needing an action from the ETP e.g: Regulation for imaging agents Make proposal to change regulation; e.g. Release position papers, motivate relevant stakeholders Preparing guidelines, recommendations IP related issues in joint projects ELSA issues Health economics specific to nanomedicine Assuring rapid movement to market of new products Transferring industrial know-how/perspective to academia Assuring access to new products across society 14

Communication & dissemination Collecting statistics, key reference documents Mapping of EU and national programmes on common framework to ensure priorities are followed and gaps are not left Opening

15 Communication & dissemination Collecting statistics, key reference documents Mapping of EU and national programmes on common framework to ensure priorities are followed and gaps are not left Opening a web site Reference documents like SRA Educational documents Forum for discussion Holding 2 meetings per year Plenary / parallel sessions Partnering / matching sessions Participating on invitation to international events Answering requests for information 15

16 Official meetings General assembly Once a year, in January Format Half day in plenary session Half day in parallel working groups (WGs) Next January 2009, in MiNaTec Grenoble, organised by CEA-LETI Technical meeting of WGs Once a year, in September Next September 2008, in Spain, organised by NeuroPharma Back to back to ESF summer school (19-24 Sept 08) 16

Outreach Information and influence of selected target groups NMP, HEALTH and ICT programme committees Other European Technology Platforms

17 Outreach Information and influence of selected target groups NMP, HEALTH and ICT programme committees Other European Technology Platforms National authorities, programme agencies Industries Raising awareness of the general public Increasing membership of industry and healthcare providers 17

18 Creating the ETP Office Diagnostics Drug delivery Regenerative medicine ELSA IPR Regulatory Affairs ETP chair(s) WG chairs Mirror Group chair Office general secretary Office ETP members Mirror Group 18

Membership fee policy Membership fee (per annum) Industry > 5,000 employees 20.000 Industry > 250 employees 10.

19 Membership fee policy Membership fee (per annum) Industry > 5,000 employees Industry > 250 employees SMEs employees SMEs <15 employees Healthcare providers Academia, research centres, and associations 500 Regions

20 Benefits for members Access to a range of means to increase the chances of EC supported joint funding for your research projects Influencing the core topics of the EU call proposals More efficient lobbying by the ETP compared to single organisation Identification of key partners and technology transfers through participation in proposal & partners meetings (matching sessions) Better understanding of and influence in nanomedicine Early learning of ongoing processes, progress and developments Deeper insight into industrial developments, demands and market changes Faster information about and access to new research results and directions Increased cooperation possibilities in nanomedicine Easier identification and access to reliable partners for collaborations at the regular platform meetings Participate in creating a leading role for the EU in Nanomedicine 20

Contribute to opinion forming Advanced information on developments for NanoMedicine in the social, IP,regulatory and reimbursement front Rights

21 Contribute to opinion forming Advanced information on developments for NanoMedicine in the social, IP,regulatory and reimbursement front Rights of members Participate at General Assemblies and Working Group meetings and have influence on them Access to the members only area of the website 21

22 For more information nanomedicine.htm

23 Thank you for your attention

Nanotechnology and Advanced Materials for more effective Healthcare

Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics